ArticleACS applied bio materials2026
Microfluidic Encapsulation of Sorafenib-Loaded ZIF-8 Nanoparticles in pH-Responsive Alginate Microparticles for Oral Chemotherapy of Hepatocellular Carcinoma.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioinspired nanoparticles deliver DNase I to attenuate ulcerative colitis by degrading NETs and modulating PTGS2-mediated ER stress.Materials today. Bio · 2026Article
- Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality. Sorafenib is the current first-line oral therapy; however, its therapeutic efficacy is limited by poor aqueous solubility, low bioavailability, and gastrointestinal instability. This study aimed to develop a pH-responsive nano-in-microparticle delivery system using a single-step droplet-based microfluidic process to protect sorafenib in the gastric environment and achieve controlled release for enhanced oral chemotherapy. Sorafenib-loaded ZIF-8 nanoparticles (SZ NPs) were synthesized and characterized by scanning electron microscopy (SEM), Fourier-transform infrared (FTIR) spectroscopy, Energy-dispersive X-ray (EDX) spectroscopy, and X-ray diffraction (XRD), exhibiting a mean diameter of about 72 nm and a drug encapsulation efficiency of 76%. These SZ NPs were subsequently encapsulated in alginate to form pH-responsive nano-in-microparticles. Computational fluid dynamics (CFD) simulations were conducted to optimize flow dynamics and droplet formation within the microfluidic channels, and particle morphology and uniformity were assessed via bright-field microscopy, fluorescence microscopy, and SEM. The resulting nano-in-microparticles exhibited spherical morphology with hydrodynamic sizes ranging from 76 to 113 μm, depending on the flow rate ratio, demonstrating uniform SZ NP dispersion. Drug release studies in simulated gastric and intestinal fluids revealed that the nano-in-microparticles prevented premature drug release in acidic simulated gastric fluid (pH < 5.7), while facilitating a controlled and sustained release profile under simulated intestinal conditions (pH 7.4) over 24 h. Cytotoxicity assays against HepG2 liver cancer cells showed significant anticancer efficacy compared to free sorafenib. These findings highlight the potential of this pH-responsive platform as an effective oral delivery strategy for HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.